CYB003 clinical trials
CYB003 is named as an intervention in 2 current clinical trials in our UK, USA, Poland, Australia, Ireland, Germany and Czechia registers. 1 is recruiting patients now. All registered phases are Phase 3. The lead sponsor is Cybin IRL Limited. The most-studied condition is Major Depressive Disorder (MDD).
Patient leaflets for CYB003
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of CYB003
2 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
NCT06793397 · Major Depressive Disorder (MDD), Depression in Adults, Depression - Major Depressive Disorder
|
Phase 3 | Recruiting | Cybin IRL Limited | Ireland, UK, USA, Germany, Poland, Czechia, Australia |
|
Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)
NCT06605105 · Major Depressive Disorder
|
Phase 3 | By invitation | Cybin IRL Limited | UK, USA, Poland, Australia |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with CYB003
5 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Cybin IRL Limited | 2 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in UK | 2 | 1 |
| Clinical trials in USA | 2 | 1 |
| Clinical trials in Poland | 2 | 1 |
| Clinical trials in Australia | 2 | 1 |
| Clinical trials in Ireland | 1 | 1 |
| Clinical trials in Germany | 1 | 1 |
| Clinical trials in Czechia | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about CYB003 trials
How many clinical trials are testing CYB003?
2 current trials in our UK, USA, Poland, Australia, Ireland, Germany and Czechia registers name CYB003 as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are CYB003 trials recruiting patients?
Yes. 1 of the 2 trials is recruiting: 1 with sites in UK, 1 with sites in USA, 1 with sites in Poland, 1 with sites in Australia, 1 with sites in Ireland, 1 with sites in Germany and 1 with sites in Czechia. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors CYB003 clinical trials?
The lead sponsor is Cybin IRL Limited. The number in brackets is how many trials each organisation leads.
Are there CYB003 clinical trials in Ireland?
Yes. 1 trial in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how CYB003 works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how CYB003 works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists CYB003 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.